TY - JOUR
T1 - Role of Corticosteroid Hormones in the Control of Cell Proliferation in Residual Tumor after Surgical Cytoreduction
AU - Braunschweiger, Paul G.
AU - Schiffer, Lewis M.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1983/12/1
Y1 - 1983/12/1
N2 - Changes in tumor cell proliferation in local and distant residual tumor were studied after subtotal surgical cytoreduction in three experimental tumor models varying in corticosteroid receptor content, cell proliferation, and animal host. In residual s.c. RIF-1 and R3230AC tumors, proliferation was inhibited within 24 h after 75% resection. Subsequently, intervals of increased proliferation, characterized by increases in tritiated thymidine ([3H]-dThd) labeling index, primer-dependent DNA polymerase labeling indices, and S-phase clonogenic fractions, were observed. In RIF-1 'artificial' lung metastases, [3H]dThd uptake in tumor-bearing lungs increased by about 70% at 3 days after amputation of 'primary' tumor-bearing legs. When dexamethasone was given every 12 hr during the postsurgical recovery interval, changes in [3H]dThd labeling indices and [3H]dThd uptake per lung indicated that the proliferative recovery was delayed until after cessation of dexamethasone treatments. Other studies with RIF-1 tumors indicated that postsurgical tumors indicated that postsurgical proliferation inhibition was dependent on intact adrenal function and that the initiation of postsurgical proliferative recovery was preceded by reestablishment of normal serum corticosterone levels and presurgical levels of saturable glucocorticosteroid receptor. The effectiveness of cyclophosphamide 5-fluorouracil after surgery was time dependent in residual local and distant tumor, with the most efficacious intervals being coincident with postsurgical proliferative recovery. Our results indicate that, in these experimental tumor models, changes in endogenous corticosteroid hormones resulting from the surgical trauma, cellular corticosteroid hormone receptor levels and cytoreduction may influence the time course of the proliferative response in residual tumor after surgical cytoreduction.
AB - Changes in tumor cell proliferation in local and distant residual tumor were studied after subtotal surgical cytoreduction in three experimental tumor models varying in corticosteroid receptor content, cell proliferation, and animal host. In residual s.c. RIF-1 and R3230AC tumors, proliferation was inhibited within 24 h after 75% resection. Subsequently, intervals of increased proliferation, characterized by increases in tritiated thymidine ([3H]-dThd) labeling index, primer-dependent DNA polymerase labeling indices, and S-phase clonogenic fractions, were observed. In RIF-1 'artificial' lung metastases, [3H]dThd uptake in tumor-bearing lungs increased by about 70% at 3 days after amputation of 'primary' tumor-bearing legs. When dexamethasone was given every 12 hr during the postsurgical recovery interval, changes in [3H]dThd labeling indices and [3H]dThd uptake per lung indicated that the proliferative recovery was delayed until after cessation of dexamethasone treatments. Other studies with RIF-1 tumors indicated that postsurgical tumors indicated that postsurgical proliferation inhibition was dependent on intact adrenal function and that the initiation of postsurgical proliferative recovery was preceded by reestablishment of normal serum corticosterone levels and presurgical levels of saturable glucocorticosteroid receptor. The effectiveness of cyclophosphamide 5-fluorouracil after surgery was time dependent in residual local and distant tumor, with the most efficacious intervals being coincident with postsurgical proliferative recovery. Our results indicate that, in these experimental tumor models, changes in endogenous corticosteroid hormones resulting from the surgical trauma, cellular corticosteroid hormone receptor levels and cytoreduction may influence the time course of the proliferative response in residual tumor after surgical cytoreduction.
UR - http://www.scopus.com/inward/record.url?scp=0021013915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021013915&partnerID=8YFLogxK
M3 - Article
C2 - 6640531
AN - SCOPUS:0021013915
VL - 43
SP - 5801
EP - 5807
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 20
ER -